Aclaris Therapeutics Reports Positive Phase 2a Clinical Trial Results for ATI-2138
Aclaris Therapeutics Inc. (NASDAQ:ACRS) is one of the most promising penny stocks under $5.
Aclaris Therapeutics Inc. (ACRS)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Adage Capital Management Phill Gross And Robert Atchinson | 9,627,304 | $13,670,772 | 0.02% | |
| 2. | Vivo Capital Albert Cha And Frank Kung | 8,888,888 | $12,622,221 | 1.29% | |
| 3. | Rock Springs Capital Management Kris Jenner, Gordon Bussard, Graham Mcphail | 4,769,309 | $6,772,419 | -6% | 0.42% |
| 4. | Decheng Capital Min Cui | 4,041,736 | $5,739,265 | 1.45% | |
| 5. | Millennium Management Israel Englander | 3,837,380 | $5,449,080 | -8% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.25 | 666,666 | $1,499,998.50 | 710,030 | 2024-11-19 | Filing | |
| $1.24 | 206,025 | $256,356.91 | 14,250,000 | 2024-08-05 | Filing | |
| $1.29 | 167,544 | $216,399.83 | 14,043,975 | 2024-08-02 | Filing | |
| $1.33 | 100,000 | $132,640.00 | 13,876,421 | 2024-07-31 | Filing | |
| $1.30 | 173,730 | $226,370.19 | 13,776,421 | 2024-07-30 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.08 | 6,000 | $30,460.20 | 129,724 | 2023-10-23 | Filing | |
| $7.32 | 6,000 | $43,894.80 | 135,724 | 2023-08-21 | Filing | |
| $10.28 | 6,000 | $61,662.60 | 141,724 | 2023-06-20 | Filing | |
| $12.63 | 30,240 | $382,070.30 | 1,273,202 | 2023-03-03 | Filing | |
| $12.37 | 29,000 | $358,587.90 | 1,285,188 | 2023-03-02 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 14,250,000 | $20,235,000 | 15.31% | |
| 2. | 6,662,063 | $9,460,130 | 0% | |
| 3. | 5,514,879 | $7,831,128 | 0% | |
| 4. | 3,540,192 | $5,027,072 | 0% | |
| 5. | 2,464,779 | $3,500,928 | 0% |
News See All
13 Most Promising Penny Stocks Under $5
On August 12, Jill Carey Hall, BofA Securities head of US small and mid-cap strategy, joined 'The Exchange' on CNBC to discuss the outlook for small caps, amidst their underperformance.
Aclaris Therapeutics Begins Phase 1 Clinical Trial for Bispecific Antibody ATI-052 Targeting Inflammatory Diseases
Aclaris Therapeutics Inc. (NASDAQ:ACRS) is one of the best low priced pharma stocks to buy now.
13 Best Low Priced Pharma Stocks to Buy Now
On July 9, Afsaneh Beschloss, RockCreek Group founder & CEO, joined 'Closing Bell Overtime' on CNBC to talk about the latest round of tariff threats.
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Q1 2024 Earnings Call Transcript
Aclaris Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.23835, expectations were $-0.28. Aclaris Therapeutics, Inc.
5 Cheap Small-Cap Stocks to Buy Before the Next Breakout
In this piece, we will take a look at five cheap small cap stocks to buy before the next breakout.
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Q1 2023 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to Aclaris Therapeutics First Quarter 2023 Conference Call. At this time, all participants are in a listen-only mode.
Did Hedge Funds Catch A Break With Aclaris Therapeutics, Inc. (ACRS)?
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 867 13F filings that hedge funds and well-known value investors are required to file by the SEC.
Is Aclaris Therapeutics, Inc. (ACRS) Going to Burn These Hedge Funds?
After several tireless days we have finished crunching the numbers from nearly 900 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed...
5 Best Healthcare Stocks to Buy According to Greg Martinez's Parkman Healthcare Partners
In this article, we discuss the 5 best healthcare stocks to buy according to Greg Martinez's Parkman Healthcare Partners.
Billionaire Hedge Funds
